Replies to post #85343 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

Good post, thanks.

[flipper44]

Good insights and reminders Doclogic. I agree.

There is a silver lining brought on by the crossover for the original treatment group as well as the original placebo group IMHO.

Since contemplating with others that potential serendipity sometime ago, I've read further literature that only strengthens my resolve regarding this informal hypothesis.

The inevitable march toward mesenchymal traits from other prior nonmesenchymal subtypes is likely a critical component to explain patients living longer than expected. As a concept, it is perhaps anathema for some to consider that, in practice, if patients live long enough, therapeutic intervention can drive the cancer toward a more aggressive, mobile and heterogenous state -- mesenchymal -- whilst researchers declare "we've got the cancer right where we want it!" Yet in principle, perhaps that is spot on, imho, for reasons discussed in other posts.

It is a great paradox that when some people are ready to throw their hands up in despair and concede another fight to cancer, DCVax-L might be in a position to knock it out -- hopefully for good -- in more and more cases as dosing, manufacturing improvements and adjuvants continue to improve and expand its reach.